ConductScience.org, home

Paper28301271

Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016).

Lai Y and 7 others. Hum Vaccin Immunother, 2017. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). Papers, record 28301271. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28301271

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016).
PubMed
Journal
Hum Vaccin Immunother
PubMed
Year
2017
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
0.58
iCite
Revised in PubMed
2018-11-13
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lai YYunfeng
2Wang RRuibing
3Chen XXin
4Tang DDaisheng
5Hu YYuanjia
6Cai JJing
7Zhang QQingwen
8Hu HHao

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
BibliometricsMajor topic
Drug DiscoveryMajor topic
Immunologic FactorsMajor topic
Animals
Biomedical Research
Humans

Source PubMed

Download CSV of topics

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125285786Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.BMC Med2014https://conductscience.org/library/papers/25285786PubMed
212778055Development of potent monoclonal antibody auristatin conjugates for cancer therapy.Nat Biotechnol2003https://conductscience.org/library/papers/12778055PubMed
312047962Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.Lancet2002https://conductscience.org/library/papers/12047962PubMed
45432063Cleavage of structural proteins during the assembly of the head of bacteriophage T4.Nature1970https://conductscience.org/library/papers/5432063PubMed
53756930Production and characterization of two human glioma xenograft-localizing monoclonal antibodies.Cancer Res1986https://conductscience.org/library/papers/3756930PubMed
68194690Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.Gastroenterology1994https://conductscience.org/library/papers/8194690PubMed
715175435Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med2004https://conductscience.org/library/papers/15175435PubMed
812584368Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.N Engl J Med2003https://conductscience.org/library/papers/12584368PubMed
97471090Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody.Cancer Res1980https://conductscience.org/library/papers/7471090PubMed
1020068188Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.Cancer Res2010https://conductscience.org/library/papers/20068188PubMed
118011287Making antibodies by phage display technology.Annu Rev Immunol1994https://conductscience.org/library/papers/8011287PubMed
1216472588Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.Gastroenterology2006https://conductscience.org/library/papers/16472588PubMed
1316904789Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.Adv Drug Deliv Rev2006https://conductscience.org/library/papers/16904789PubMed
143102250The use of hybrid hybridomas to target human cytotoxic T lymphocytes.Eur J Immunol1987https://conductscience.org/library/papers/3102250PubMed
158159246Antigen-specific human antibodies from mice comprising four distinct genetic modifications.Nature1994https://conductscience.org/library/papers/8159246PubMed
1625077605Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014).Expert Opin Biol Ther2014https://conductscience.org/library/papers/25077605PubMed
179321530A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.N Engl J Med1997https://conductscience.org/library/papers/9321530PubMed
1823438745Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.Chem Biol2013https://conductscience.org/library/papers/23438745PubMed
1923678006Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.Blood2013https://conductscience.org/library/papers/23678006PubMed
2025568796The history of monoclonal antibody development - Progress, remaining challenges and future innovations.Ann Med Surg (Lond)2014https://conductscience.org/library/papers/25568796PubMed

See all 62 referencesDownload CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
39152301Immunotherapy for small cell lung cancer: the current state and future trajectories.Discov Oncol2024https://conductscience.org/library/papers/39152301PubMed
36568760Bibliometric and visual analysis of cardiovascular diseases and COVID-19 research.Front Public Health2022https://conductscience.org/library/papers/36568760PubMed
36137125Bibliometric analysis of hotspots and frontiers in cancer-related fatigue among ovarian cancer survivors.PLoS One2022https://conductscience.org/library/papers/36137125PubMed
33628140Technological Advancements in Monoclonal Antibodies.ScientificWorldJournal2021https://conductscience.org/library/papers/33628140PubMed
33363597A new era for monoclonal antibodies with applications in neurology (Review).Exp Ther Med2021https://conductscience.org/library/papers/33363597PubMed
33194520Comparative analytical profiling of bevacizumab biosimilars marketed in India: a national control laboratory study.3 Biotech2020https://conductscience.org/library/papers/33194520PubMed
31483112Western Blotting with Solutions containing Nanoliter Volumes of Antibody.Curr Protoc Cell Biol2019https://conductscience.org/library/papers/31483112PubMed
30539362Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.BioDrugs2019https://conductscience.org/library/papers/30539362PubMed
29293380Trends involving monoclonal antibody (mAb) research and commercialization: A scientometric analysis of IMS Lifecycle R&D Focus Database (1980-2016).Hum Vaccin Immunother2018https://conductscience.org/library/papers/29293380PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28301271

GET https://conductscience.org/api/papers/v1/28301271/references?page=2